Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Uterine Cervical Neoplasms

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Antineoplastic Agents

All Drugs and Chemicals

Cisplatin

EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A

EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT

EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A

Radiotherapy alone

EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT

Radiotherapy with cisplatin

Eduardo H. Zubizarreta, M.D.

Reena Engineer, MD

Twalib Ngoma, MD

Joseph Kigula, MD

The researchers plan:

* To undertake clinical studies of radiotherapy with or without the administration of the chemotherapeutic agent cisplatin, known to be a radiosensitizer;
* To perform pre-clinical studies of the radiosensitivity of human fibroblasts and cervical cancer cell lines in culture, with or without the addition of various HIV proteins or protease inhibitors, in order to determine the extent of any cellular radiosensitizing properties of these molecules;
* To develop strategies for sensitizing tumour cells to radiation, specifically by down-regulating specific viral proteins that are known to be factors associated with resistance to radiotherapy.

Clinical study addresses the question of whether radiotherapy plus weekly cisplatin offers an advantage over the same radiotherapy given alone in AIDS patients with cervix cancer. External beam radiotherapy is used with 50 Gy in 25 daily fractions (last interim analysis, October 2005) suggested lowering the total dose down to 46 Gy in 23 daily fractions). Brachytherapy component was specified as either 30 Gy of LDR in a single fraction or 3 fractions of 8 Gy using HDR. Cisplatin was administered weekly at a dose of 30 mg/sqm.

Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients

Doctoral CRP on Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients

International Atomic Energy Agency

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients	NCT00122746	Cancer of the C...	Radiotherapy al... Radiotherapy wi...	18 Years -	International Atomic Energy Agency
Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients	NCT00122746	Cancer of the C...	Radiotherapy al... Radiotherapy wi...	18 Years -	International Atomic Energy Agency
Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients	NCT00122746	Cancer of the C...	Radiotherapy al... Radiotherapy wi...	18 Years -	International Atomic Energy Agency

Spots Global Cancer Trial Database for radiotherapy with cisplatin